View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAmur Minerals 과거 순이익 실적과거 기준 점검 0/6Amur Minerals의 연간 평균 수익은 6.4%였으며, Metals and Mining 산업의 수익은 연간 9.4% 감소했습니다.핵심 정보6.39%순이익 성장률27.03%주당순이익(EPS) 성장률Metals and Mining 산업 성장률26.40%매출 성장률n/a자기자본이익률-62.88%순이익률n/a최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트공고 • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024모든 업데이트 보기Recent updates공고 • Mar 31CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation ApplicationCRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify.공고 • Mar 28CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UKCRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed.공고 • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024공고 • May 15Amur Minerals Corporation, Annual General Meeting, May 29, 2024Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom공고 • Nov 13Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom공고 • Sep 25Amur Minerals Corporation Announces Special DividendAmur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment.공고 • Sep 07Amur Minerals Announces Suspension of Trading on AIMAmur Minerals Corporation confirmed that trading in the Company's shares on AIM will be suspended with effect from 7.30 a.m. BST 7 September 2023. As stated in the Company's notification of 6 March 2023, following the disposal of the Company's AO Kun-Manie subsidiary, Amur became classified as an AIM Rule 15 cash shell from that date, and as such was required to make an acquisition or acquisitions which would constitute a reverse takeover under Rule 14 of the AIM Rules for Companies, or be re-admitted on AIM as an investing company under the AIM Rules on or before the date falling six months from 6 March 2023. As neither a reverse takeover nor readmission to trading on AIM as an investing company have been completed, trading in the Company's shares on AIM will now be suspended on7 September 2023. Trading will remain suspended until the completion of a reverse takeover, which requires the publication of an admission document and the approval of such a transaction at a General Meeting of the Company, or the Company is readmitted to trading on AIM as an investing company. If no such transaction is completed within six months, the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41. There can be no assurance that the Company will be able to complete a reverse takeover during the six-month suspension period. The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate.공고 • Aug 10Amur Minerals Corporation Announces Cessation of Discussions with Ascent Resources PlcAscent Resources Plc (AIM:AST) ("Ascent" or, the "Company"), noted Amur Minerals Corporation (AIM:AMC) ("Amur") announcement, regarding the cessations of discussions regarding thenon-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent. Ascent is surprised and disappointed with this announcement given the last communication between the parties was three weeks ago with Ascent confirming its forward process and timetables to achieve the possible combination, following which Ascent has been waiting for the Amur board to engage further on the proposal. Given that Ascent is expecting imminently the result of its €3.5 million+ arbitration claim against its JV partner in Slovenia, Ascent still believes that a combination of the two companies would be in the interest of both shareholder groups. Accordingly, Ascent is exploring the possibility to put forward a binding offer to the shareholders for the issued and to be issued share capital of Amur.공고 • Jun 02Ascent Resources Announces Intention to Bid for Amur MineralsThe board of directors of Ascent Resources Plc (AIM:AST) announced their intention to bid for the entire issued and to be issued share capital of Amur Minerals Corporation (AIM:AMC) following a period of protracted discussions with the Board of Amur. Ascent's vision is that Ascent and Amur would combine to form a larger, well funded and more liquid, entity combining Amur's cash (post the recently announced asset sale and subsequent dividend) with Ascent's ESG Metals project pipeline in LATAM, which typically have low geological risk and near term and sustainable cashflows, in addition to the significant upside exposure of Ascent's funded EUR 500+ million Energy Charter Treaty damages claim(the "Potential Combination"). Ascent submitted a non-binding indicative proposal to the Board of Amur in November 2022 to acquire 100% of the issued and to be issued share capital of Amur (post payment of its dividend as subsequently announced 24 May 2023) in a share-for-share exchange on a ratio of approximately 1 new Ascent share for every 21 Amur shares in issue (the "Exchange Ratio") (subject to the reservations set out below) (the "Indicative Proposal"). On the assumption that Amur only has assets of $5,000,000 in cash (post payment of dividend) and no further material liabilities, the indicative proposal is equivalent to a gross equity valuation of 6.1 pence per new Ascent share (based on an exchange rate of $1 = £0.8051). Despite multiple conversations with the Board of Amur and multiple follow up correspondence, the Company has as yet been unable to elicit a written response to their offer. The Indicative Proposal also included the intention to combine the skills of both executive teams, as well as other potential changes to the enlarged groups non-executive directors. It is intended that the enlarged group would have a majority of board directors from Ascent. The Exchange Ratio, based on Ascents volume weighted average share price of 3.6716 pence yesterday, being the last business day immediately prior to the date of this announcement, currently represents a value of approximately 0.175 pence per Amur share. At the current value of approximately 0.175 pence per Amur share implied by the Exchange Ratio, a potential offer, if made, when added to the 1.8 pence dividend to be paid by Amur would represent a premium of approximately: 7.3%. to the Amur closing price of 1.840 pence per share on 31 May 2023, being the last business day immediately prior to this announcement; 15.3%. to the monthly average volume weighted average price calculations for Amur shares over the three-month period starting on and including 1 March 2023, being 1.713 pence per share; and 47.5%. to the monthly average volume weighted average price for Amur shares over the six-month period starting on and including 1 December 2022, being 1.339 pence per share Under the terms of the Indicative Proposal, it is expected that Amur shareholders would own approximately 28.6%. of the enlarged group, and Ascent shareholders would own approximately 71.4%. of the enlarged group. Given the Indicative Proposal is currently proposed to be structured as an share-for-share exchange effected by either scheme of arrangement or plan of arrangement, Ascent is currently only minded to proceed with the Indicative Proposal on the pre-condition that a recommendation from the Amur Board is ultimately forthcoming.공고 • May 25Amur Minerals Corporation Announces Special Dividend, Payable on June 14, 2023Amur Minerals Corporation provide an update on the issuance of its special dividend of 1.8 pence per share. The special dividend is to be paid out of the funds received for the sale of its Russian Federation Kun-Manie nickel -copper asset. As the funds have been sourced from a non-sanctioned entity in Russia, payment of the dividend has required extraordinary non-typical enhanced governance approaches for implementation of payment. Shareholders of record at the close of business 2 June 2023 will be entitled to payment of the dividend projected to be 14 June 2023. The shares will go ex-dividend on 1 June 2023.매출 및 비용 세부 내역Amur Minerals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:AMMC.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 230-32031 Mar 230-32031 Dec 220-32030 Jun 220-42031 Mar 220-32031 Dec 210-22030 Jun 210-13031 Mar 210-23031 Dec 200-33030 Sep 200-33030 Jun 200-32031 Mar 200-22031 Dec 190-22030 Sep 190-32030 Jun 190-32031 Mar 190-32031 Dec 180-32030 Sep 180-42030 Jun 180-42031 Mar 180-32031 Dec 170-12030 Sep 170-22030 Jun 170-22031 Mar 170-43031 Dec 160-64030 Sep 160-65030 Jun 160-65031 Mar 160-35031 Dec 150-14030 Sep 15033030 Jun 15072031 Mar 15032031 Dec 140-12030 Sep 140-42030 Jun 140-72031 Mar 140-52031 Dec 130-42030 Sep 130-22030 Jun 13002031 Mar 130-220양질의 수익: AMMC.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: AMMC.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: AMMC.F는 수익성이 없지만 지난 5년 동안 연평균 6.4%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 AMMC.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: AMMC.F은 수익성이 없어 지난 해 수익 성장률을 Metals and Mining 업계(82.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: AMMC.F는 현재 수익성이 없으므로 자본 수익률이 음수(-62.88%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/10/07 14:10종가2023/07/10 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CRISM Therapeutics Corporation는 2명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Lord AshbourneEdison Investment ResearchDesmond KilaleaRBC Capital Markets
공고 • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024
공고 • Mar 31CRISM Therapeutics Corporation Provides Positive Update Regarding Its Clinical Trial Authorisation ApplicationCRISM Therapeutics Corporation provided a positive update regarding its clinical trial authorisation application to evaluate irinotecan ChemoSeed in patients with high grade glioma. CRISM has been working with the Medicines and Healthcare products Regulatory Agency to finalise the design of the first in-human trial of ChemoSeed and is pleased to confirm it has received positive written scientific advice from the MHRA on the development, clinical trial programme and potential Market Authorisation Application for the commercialisation of ChemoSeed. The written advice confirms that further preclinical toxicology studies will not be required, which will significantly reduce the cost and time of the development work. The Company had previously estimated a cost of approximately PS400,000 to conduct the toxicology studies. In addition, the MHRA agreed that there is a biological basis supporting the benefits of ChemoSeed and that more drugs and methods of delivery are needed for this disease. MHRA was supportive of CRISM's novel dose escalation study for ChemoSeed, confirming that the trial design was appropriate for a Phase 2 clinical trial. The MHRA provided recommendations to improve aspects of the clinical trial to make it more suited to achieving potential market authorisation. The Company is now progressing these recommendations, with support and advice from its contract research organisation, Aixial, and its medical advisers. The Company expects to finalise its CTA application for submission in first quarter 2025 and to begin clinical trials of ChemoSeed in fourth quarter 2025, subject to MHRA and other external regulatory organizations meeting expected review times. The Company has also appointed Ryan LLC, which has a specialisation in accessing grant funding, to assist CRISM secure grant funding specifically for this clinical trial. Ryan has an excellent track record in achieving successful grant applications and has already identified opportunities for which ChemoSeed is likely to qualify.
공고 • Mar 28CRISM Therapeutics Corporation Announces Grant Awarded by Innovate UKCRISM Therapeutics Corporation announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer (the "Project"). The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the Aim market last year and which highlighted the potential of ChemoSeed in multiple disease areas. The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. Under the terms of the grant, CRISM will develop a docetaxel-loaded implantable drug delivery technology ("docetaxel ChemoSeed") for intraprostatic chemotherapy, addressing the critical need for localised, effective, and less toxic prostate cancer treatment. Docetaxel ChemoSeed is differentiated from other approaches in that it is implanted inside the prostate, overcoming the non-lipophilic characteristics of the prostate which prevent traditional chemotherapy from having a therapeutic effect. The Project, which will take about 12 months, is designed to deliver: A functional prototype of the implantable device; Pre-clinical validation data demonstrating safety and efficacy; IP protection through patents for core innovations; Scalable manufacturing protocols for commercialisation. The outputs from the Project will establish a foundation for the design of clinical trials, the regulatory approval pathway and market introduction, addressing a critical unmet medical need in prostate cancer therapy. The total cost of the Project is £152,550, and covers key areas such as staffing, overheads, subcontracting, preclinical validation, and regulatory and IP advice. The Company is receiving a grant of £96,106, which represents 63% of the total cost. The remaining £56,444 will be funded through contributions from CRISM. The Project will be carried out in partnership with Ulster University, Queen's University Belfast and Axis Bio, a preclinical contract research organisation, which will complete the preclinical validation to assess the efficacy and safety of the docetaxel ChemoSeed.
공고 • Sep 09CRISM Therapeutics Corporation to Report First Half, 2024 Results on Sep 19, 2024CRISM Therapeutics Corporation announced that they will report first half, 2024 results on Sep 19, 2024
공고 • May 15Amur Minerals Corporation, Annual General Meeting, May 29, 2024Amur Minerals Corporation, Annual General Meeting, May 29, 2024. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom
공고 • Nov 13Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023Amur Minerals Corporation, Annual General Meeting, Nov 30, 2023, at 10:00 Coordinated Universal Time. Location: offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane London United Kingdom
공고 • Sep 25Amur Minerals Corporation Announces Special DividendAmur Minerals Corporation announced to pay a one-time special dividend of 1.8 pence per ordinary share within 90 days of receipt of the completion payment.
공고 • Sep 07Amur Minerals Announces Suspension of Trading on AIMAmur Minerals Corporation confirmed that trading in the Company's shares on AIM will be suspended with effect from 7.30 a.m. BST 7 September 2023. As stated in the Company's notification of 6 March 2023, following the disposal of the Company's AO Kun-Manie subsidiary, Amur became classified as an AIM Rule 15 cash shell from that date, and as such was required to make an acquisition or acquisitions which would constitute a reverse takeover under Rule 14 of the AIM Rules for Companies, or be re-admitted on AIM as an investing company under the AIM Rules on or before the date falling six months from 6 March 2023. As neither a reverse takeover nor readmission to trading on AIM as an investing company have been completed, trading in the Company's shares on AIM will now be suspended on7 September 2023. Trading will remain suspended until the completion of a reverse takeover, which requires the publication of an admission document and the approval of such a transaction at a General Meeting of the Company, or the Company is readmitted to trading on AIM as an investing company. If no such transaction is completed within six months, the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41. There can be no assurance that the Company will be able to complete a reverse takeover during the six-month suspension period. The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate.
공고 • Aug 10Amur Minerals Corporation Announces Cessation of Discussions with Ascent Resources PlcAscent Resources Plc (AIM:AST) ("Ascent" or, the "Company"), noted Amur Minerals Corporation (AIM:AMC) ("Amur") announcement, regarding the cessations of discussions regarding thenon-binding indicative proposal of a possible share offer for the entire issued and to be issued share capital of Amur by Ascent. Ascent is surprised and disappointed with this announcement given the last communication between the parties was three weeks ago with Ascent confirming its forward process and timetables to achieve the possible combination, following which Ascent has been waiting for the Amur board to engage further on the proposal. Given that Ascent is expecting imminently the result of its €3.5 million+ arbitration claim against its JV partner in Slovenia, Ascent still believes that a combination of the two companies would be in the interest of both shareholder groups. Accordingly, Ascent is exploring the possibility to put forward a binding offer to the shareholders for the issued and to be issued share capital of Amur.
공고 • Jun 02Ascent Resources Announces Intention to Bid for Amur MineralsThe board of directors of Ascent Resources Plc (AIM:AST) announced their intention to bid for the entire issued and to be issued share capital of Amur Minerals Corporation (AIM:AMC) following a period of protracted discussions with the Board of Amur. Ascent's vision is that Ascent and Amur would combine to form a larger, well funded and more liquid, entity combining Amur's cash (post the recently announced asset sale and subsequent dividend) with Ascent's ESG Metals project pipeline in LATAM, which typically have low geological risk and near term and sustainable cashflows, in addition to the significant upside exposure of Ascent's funded EUR 500+ million Energy Charter Treaty damages claim(the "Potential Combination"). Ascent submitted a non-binding indicative proposal to the Board of Amur in November 2022 to acquire 100% of the issued and to be issued share capital of Amur (post payment of its dividend as subsequently announced 24 May 2023) in a share-for-share exchange on a ratio of approximately 1 new Ascent share for every 21 Amur shares in issue (the "Exchange Ratio") (subject to the reservations set out below) (the "Indicative Proposal"). On the assumption that Amur only has assets of $5,000,000 in cash (post payment of dividend) and no further material liabilities, the indicative proposal is equivalent to a gross equity valuation of 6.1 pence per new Ascent share (based on an exchange rate of $1 = £0.8051). Despite multiple conversations with the Board of Amur and multiple follow up correspondence, the Company has as yet been unable to elicit a written response to their offer. The Indicative Proposal also included the intention to combine the skills of both executive teams, as well as other potential changes to the enlarged groups non-executive directors. It is intended that the enlarged group would have a majority of board directors from Ascent. The Exchange Ratio, based on Ascents volume weighted average share price of 3.6716 pence yesterday, being the last business day immediately prior to the date of this announcement, currently represents a value of approximately 0.175 pence per Amur share. At the current value of approximately 0.175 pence per Amur share implied by the Exchange Ratio, a potential offer, if made, when added to the 1.8 pence dividend to be paid by Amur would represent a premium of approximately: 7.3%. to the Amur closing price of 1.840 pence per share on 31 May 2023, being the last business day immediately prior to this announcement; 15.3%. to the monthly average volume weighted average price calculations for Amur shares over the three-month period starting on and including 1 March 2023, being 1.713 pence per share; and 47.5%. to the monthly average volume weighted average price for Amur shares over the six-month period starting on and including 1 December 2022, being 1.339 pence per share Under the terms of the Indicative Proposal, it is expected that Amur shareholders would own approximately 28.6%. of the enlarged group, and Ascent shareholders would own approximately 71.4%. of the enlarged group. Given the Indicative Proposal is currently proposed to be structured as an share-for-share exchange effected by either scheme of arrangement or plan of arrangement, Ascent is currently only minded to proceed with the Indicative Proposal on the pre-condition that a recommendation from the Amur Board is ultimately forthcoming.
공고 • May 25Amur Minerals Corporation Announces Special Dividend, Payable on June 14, 2023Amur Minerals Corporation provide an update on the issuance of its special dividend of 1.8 pence per share. The special dividend is to be paid out of the funds received for the sale of its Russian Federation Kun-Manie nickel -copper asset. As the funds have been sourced from a non-sanctioned entity in Russia, payment of the dividend has required extraordinary non-typical enhanced governance approaches for implementation of payment. Shareholders of record at the close of business 2 June 2023 will be entitled to payment of the dividend projected to be 14 June 2023. The shares will go ex-dividend on 1 June 2023.